Stay Ahead in Fast-Growing Economies.
Browse Reports Now
Monkeypox Treatment Market Size, Share, Growth & Forecast (2024-2032)
Monkeypox Treatment Market Size Was Valued at USD 93.85 Million in 2023, and is Projected to Reach USD 226.05 Million by 2032, Growing at a CAGR of 10.26% From 2024-2032.
IMR Group
Description
Monkeypox Treatment Market Synopsis:
Monkeypox Treatment Market Size Was Valued at USD 93.85 Million in 2023, and is Projected to Reach USD 226.05 Million by 2032, Growing at a CAGR of 10.26% From 2024-2032.
Monkeypox Treatment Market centers on the pharmaceutical and medical industries in relation to the treatment of monkeypox, a viral disease resulting from the contact with the monkeypox virus, which is nearer to smallpox but not as malignant. The treatments involve controlling symptoms, avoiding the development of complications and slowing the transmission of the virus. Symptoms’ management interventions include antiviral drugs, vaccines, as well supportive care.
The Monkeypox treatment market has attracted much focus due to a rise in Monkeypox outbreaks across the globe. Transmitted by animals such as monkeys, rodents, and many types of primates, this viral disease manifests similar to flu, as well as rashes and in some cases, dangerous complications. Due to short known cases of monkeypox across many parts, the need for accurate treatments gains increased importance and hence has attracted a wakeup call from various players including governments, healthcare providers and manufacturers.
Antiviral drugs, vaccines and manage supportive care are the common treatments given to patient with monkeypox. Tecovirimat for instance been effective in managing mild and severe forms of smallpox, besides containing the spread of the virus. However, prevention measure such as immunization through vaccines such as nascent smallpox vaccine have been used in monkeypox prevention. The major helpful general measures include fluid and electrolyte balance, control of pain, and the use of anti-inflammatory agents.
Monkeypox has received increased R&D interest to identify specific treatments for the disease since the treatment market has emerged. The governments of the world have joined hand with the pharmaceutical companies so that adequate stock of antiviral medicines and vaccines are available for the people in any epidemic. Furthermore, there has been an application of prior treatments that were used in smallpox but the next level of treatment for monkeypox are being developed through present clinical trials and researches.
The general development of campaigns to improve people’s health and the shift to understanding that it is important to be ready for new viral diseases also stimulate it. Since monkeypox has affected several continents, there is more awareness about coming up with vaccines as well as antiviral drugs, enhancing the growth of imperative treatment. They opine that market is expected to further grow with the introduction of enhanced therapy line with parallel enhancement in health care system focusing to combat more effectively viral disease.
Monkeypox Treatment Market Trend Analysis:
Increased Investment in Research and Development
Rising investment from the governments and pharma manufacturers in research and development for monkeypox treatment drugs is a chief factor boosting the market trend. There is an increased investment on the part of pharma firms and research institutes in the battle against the virus on the part of both the virus and potential therapies. This trend is fostered by need to tackle new emerging outbreaks and increasing need for the effective treatment from worldwide. There is growth in the enrollment of the clinical trials, as well as the collaboration between the public and private sectors in the creation of specific antiviral reagents for monkeypox treatment.
This investment has had a positive impact on an innovative development of the new types of the vaccine and new approaches towards its usage to increase the outcome. In addition, this norm will enhance next-generation treatment possibilities and dispositions to monkeypox or other similar diseases’ outbreaks in the future. The rise in investment on R&D is expected to help sustain the increased pace of the growth of the market in further advancing the treatment options for monkeypox.
Expansion of Vaccine Programs
The monkeypox treatment market has now a new growing trend which is in the area of vaccination. With governments and health organizations realizing the importance of prior prevention measures, monkeypox has a chance to become a disease with a highly effective vaccine available for the broad public. The current smallpox vaccines that have helped to restrain monkey pox could be deployed to more communities or used frequently in areas of frequent attacks or high-risk groups.
Opportunity also include the distribution of vaccines across the world and in partnership with agencies such as WHO. Each time new information surfaces about how effective these specific vaccines are, such an opportunity has been opened for production and distribution of such vaccines by relevant pharma companies. If more vaccines are administered, then it may be possible to avoid future contagion trends for monkeypox as well as lesser the severity of cases on health systems as well as peoples across the world.
Monkeypox Treatment Market Segment Analysis:
Monkeypox Treatment Market is Segmented on the basis of Technology Type, Drug Class, Distribution Channel, and Region.
By Treatment Type, Antiviral Medications segment is expected to dominate the market during the forecast period
The monkeypox treatment market can be segmented into three main categories: medications, vaccines and other agents as well as supportive care. Pharmacological management of virus replication is done through anti-viral drugs with tecovirimat mentioned to have a significant impact to the virus spread and handling of its symptoms. These antiviral agents work by suggesting the virus replication and this gave a direct way to confronting the infection.
The prevention of monkeypox involves wanting vaccines especially old type smallpox vaccines in special risky groups in the society. These vaccines’ efficacy is particularly important in controlling the virus spread during the epidemic periods. Palliative care still forms part of intervention since the patients suffer symptoms like fever, rashes, and lack of adequate fluids. These combined treatments help to address the disease and its advancement in order to provide optimized outcomes for sufferers.
By Drug Class, Antiviral Agents segment expected to held the largest share
The segmentation in the monkeypox treatment market is based on the drug classes as the primary segment encompassing antiviral agents and immune modulators. Specific antiviral drugs, including tecovirimat, are used to block the multiplication of the virus and decrease people’s symptoms chance and transmissibility. It remains for these drugs to be use in managing the acute phases of the infection and to avoid complications and these are the reasons why these are main stays in the treatment of the infection.
System modulators on the other hand are drugs that tend to boost the body’s immunity to the virus. These agents assist to strengthen the immunity of ones body in order to be in a position to combat the sickness. Antivirals act on the virus whereas immunomodulators operate on the general capacity to combat virus through help to enhance body’s immunity. The synergy offered by these drug classes will act to improve the treatment outcomes and consequently the impact of monkeypox outbreaks.
Monkeypox Treatment Market Regional Insights:
North America is Expected to Dominate the Market Over the Forecast period
The monkeypox treatment market is currently most developed in North America due to large investments in healthcare, strong industries, and enforcement of insurance coverage. The government of both the United States and of other regions such as Canada have expressed early concern towards new infectious diseases, including monkeypox. The region can manage the spread of such diseases if antiviral options and preventable measures such as vaccines are available on the market.
North American market is also backed up by notable research activities with most pharma majors of the region also involved in the research for the cure of monkeypox. Besides, the ongoing efforts in the course of disease prevention and control include vaccination and continued surveillance in the community. Since the US and other north American countries have robust healthcare infrastructure and have good research funds from the government this market is expected to hold its position of being a largest consumer in monkeypox treatment market in the future.
Active Key Players in the Monkeypox Treatment Market:
Bavarian Nordic (Denmark)
Siga Technologies, Inc. (USA)
Johnson & Johnson (USA)
Merck & Co., Inc. (USA)
Pfizer Inc. (USA)
Viroclinics Biosciences (Netherlands)
Moderna, Inc. (USA)
GlaxoSmithKline plc (UK)
Sanofi (France)
Novavax, Inc. (USA)
Emergent BioSolutions Inc. (USA)
Takeda Pharmaceutical Company Limited (Japan)
Other Active Players
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter’s Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Monkeypox Treatment Market by Treatment Type
4.1 Monkeypox Treatment Market Snapshot and Growth Engine
4.2 Monkeypox Treatment Market Overview
4.3 Antiviral Medications
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Antiviral Medications: Geographic Segmentation Analysis
4.4 Vaccines
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Vaccines: Geographic Segmentation Analysis
4.5 Supportive Care
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Supportive Care: Geographic Segmentation Analysis
Chapter 5: Monkeypox Treatment Market by Drug Class
5.1 Monkeypox Treatment Market Snapshot and Growth Engine
5.2 Monkeypox Treatment Market Overview
5.3 Antiviral Agents
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Antiviral Agents: Geographic Segmentation Analysis
5.4 Immune Modulators
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Immune Modulators: Geographic Segmentation Analysis
Chapter 6: Monkeypox Treatment Market by Distribution Channel
6.1 Monkeypox Treatment Market Snapshot and Growth Engine
6.2 Monkeypox Treatment Market Overview
6.3 Hospitals
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Hospitals: Geographic Segmentation Analysis
6.4 Clinics
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Clinics: Geographic Segmentation Analysis
6.5 Retail Pharmacies
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Retail Pharmacies: Geographic Segmentation Analysis
6.6 Online Pharmacies
6.6.1 Introduction and Market Overview
6.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.6.3 Key Market Trends, Growth Factors and Opportunities
6.6.4 Online Pharmacies: Geographic Segmentation Analysis
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Benchmarking
7.1.2 Monkeypox Treatment Market Share by Manufacturer (2023)
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Mergers and Acquisitions
7.2 BAVARIAN NORDIC (DENMARK)
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Role of the Company in the Market
7.2.5 Sustainability and Social Responsibility
7.2.6 Operating Business Segments
7.2.7 Product Portfolio
7.2.8 Business Performance
7.2.9 Key Strategic Moves and Recent Developments
7.2.10 SWOT Analysis
7.3 SIGA TECHNOLOGIES INC. (USA)
7.4 JOHNSON & JOHNSON (USA)
7.5 MERCK & CO. INC. (USA)
7.6 PFIZER INC. (USA)
7.7 VIROCLINICS BIOSCIENCES (NETHERLANDS)
7.8 MODERNA INC. (USA)
7.9 GLAXOSMITHKLINE PLC (UK)
7.10 SANOFI (FRANCE)
7.11 NOVAVAX INC. (USA)
7.12 EMERGENT BIOSOLUTIONS INC. (USA)
7.13 TAKEDA PHARMACEUTICAL COMPANY LIMITED (JAPAN)
7.14 OTHER ACTIVE PLAYERS
Chapter 8: Global Monkeypox Treatment Market By Region
8.1 Overview
8.2. North America Monkeypox Treatment Market
8.2.1 Key Market Trends, Growth Factors and Opportunities
8.2.2 Top Key Companies
8.2.3 Historic and Forecasted Market Size by Segments
8.2.4 Historic and Forecasted Market Size By Treatment Type
8.2.4.1 Antiviral Medications
8.2.4.2 Vaccines
8.2.4.3 Supportive Care
8.2.5 Historic and Forecasted Market Size By Drug Class
8.2.5.1 Antiviral Agents
8.2.5.2 Immune Modulators
8.2.6 Historic and Forecasted Market Size By Distribution Channel
8.2.6.1 Hospitals
8.2.6.2 Clinics
8.2.6.3 Retail Pharmacies
8.2.6.4 Online Pharmacies
8.2.7 Historic and Forecast Market Size by Country
8.2.7.1 US
8.2.7.2 Canada
8.2.7.3 Mexico
8.3. Eastern Europe Monkeypox Treatment Market
8.3.1 Key Market Trends, Growth Factors and Opportunities
8.3.2 Top Key Companies
8.3.3 Historic and Forecasted Market Size by Segments
8.3.4 Historic and Forecasted Market Size By Treatment Type
8.3.4.1 Antiviral Medications
8.3.4.2 Vaccines
8.3.4.3 Supportive Care
8.3.5 Historic and Forecasted Market Size By Drug Class
8.3.5.1 Antiviral Agents
8.3.5.2 Immune Modulators
8.3.6 Historic and Forecasted Market Size By Distribution Channel
8.3.6.1 Hospitals
8.3.6.2 Clinics
8.3.6.3 Retail Pharmacies
8.3.6.4 Online Pharmacies
8.3.7 Historic and Forecast Market Size by Country
8.3.7.1 Russia
8.3.7.2 Bulgaria
8.3.7.3 The Czech Republic
8.3.7.4 Hungary
8.3.7.5 Poland
8.3.7.6 Romania
8.3.7.7 Rest of Eastern Europe
8.4. Western Europe Monkeypox Treatment Market
8.4.1 Key Market Trends, Growth Factors and Opportunities
8.4.2 Top Key Companies
8.4.3 Historic and Forecasted Market Size by Segments
8.4.4 Historic and Forecasted Market Size By Treatment Type
8.4.4.1 Antiviral Medications
8.4.4.2 Vaccines
8.4.4.3 Supportive Care
8.4.5 Historic and Forecasted Market Size By Drug Class
8.4.5.1 Antiviral Agents
8.4.5.2 Immune Modulators
8.4.6 Historic and Forecasted Market Size By Distribution Channel
8.4.6.1 Hospitals
8.4.6.2 Clinics
8.4.6.3 Retail Pharmacies
8.4.6.4 Online Pharmacies
8.4.7 Historic and Forecast Market Size by Country
8.4.7.1 Germany
8.4.7.2 UK
8.4.7.3 France
8.4.7.4 The Netherlands
8.4.7.5 Italy
8.4.7.6 Spain
8.4.7.7 Rest of Western Europe
8.5. Asia Pacific Monkeypox Treatment Market
8.5.1 Key Market Trends, Growth Factors and Opportunities
8.5.2 Top Key Companies
8.5.3 Historic and Forecasted Market Size by Segments
8.5.4 Historic and Forecasted Market Size By Treatment Type
8.5.4.1 Antiviral Medications
8.5.4.2 Vaccines
8.5.4.3 Supportive Care
8.5.5 Historic and Forecasted Market Size By Drug Class
8.5.5.1 Antiviral Agents
8.5.5.2 Immune Modulators
8.5.6 Historic and Forecasted Market Size By Distribution Channel
8.5.6.1 Hospitals
8.5.6.2 Clinics
8.5.6.3 Retail Pharmacies
8.5.6.4 Online Pharmacies
8.5.7 Historic and Forecast Market Size by Country
8.5.7.1 China
8.5.7.2 India
8.5.7.3 Japan
8.5.7.4 South Korea
8.5.7.5 Malaysia
8.5.7.6 Thailand
8.5.7.7 Vietnam
8.5.7.8 The Philippines
8.5.7.9 Australia
8.5.7.10 New Zealand
8.5.7.11 Rest of APAC
8.6. Middle East & Africa Monkeypox Treatment Market
8.6.1 Key Market Trends, Growth Factors and Opportunities
8.6.2 Top Key Companies
8.6.3 Historic and Forecasted Market Size by Segments
8.6.4 Historic and Forecasted Market Size By Treatment Type
8.6.4.1 Antiviral Medications
8.6.4.2 Vaccines
8.6.4.3 Supportive Care
8.6.5 Historic and Forecasted Market Size By Drug Class
8.6.5.1 Antiviral Agents
8.6.5.2 Immune Modulators
8.6.6 Historic and Forecasted Market Size By Distribution Channel
8.6.6.1 Hospitals
8.6.6.2 Clinics
8.6.6.3 Retail Pharmacies
8.6.6.4 Online Pharmacies
8.6.7 Historic and Forecast Market Size by Country
8.6.7.1 Turkiye
8.6.7.2 Bahrain
8.6.7.3 Kuwait
8.6.7.4 Saudi Arabia
8.6.7.5 Qatar
8.6.7.6 UAE
8.6.7.7 Israel
8.6.7.8 South Africa
8.7. South America Monkeypox Treatment Market
8.7.1 Key Market Trends, Growth Factors and Opportunities
8.7.2 Top Key Companies
8.7.3 Historic and Forecasted Market Size by Segments
8.7.4 Historic and Forecasted Market Size By Treatment Type
8.7.4.1 Antiviral Medications
8.7.4.2 Vaccines
8.7.4.3 Supportive Care
8.7.5 Historic and Forecasted Market Size By Drug Class
8.7.5.1 Antiviral Agents
8.7.5.2 Immune Modulators
8.7.6 Historic and Forecasted Market Size By Distribution Channel
8.7.6.1 Hospitals
8.7.6.2 Clinics
8.7.6.3 Retail Pharmacies
8.7.6.4 Online Pharmacies
8.7.7 Historic and Forecast Market Size by Country
8.7.7.1 Brazil
8.7.7.2 Argentina
8.7.7.3 Rest of SA
Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies
Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research
Q1: What would be the forecast period in the Monkeypox Treatment Market research report?
A1: The forecast period in the Monkeypox Treatment Market research report is 2024-2032.
Q2: Who are the key players in the Monkeypox Treatment Market?
A2: Bavarian Nordic (Denmark), Siga Technologies, Inc. (USA), Johnson & Johnson (USA), Merck & Co., Inc. (USA), Pfizer Inc. (USA), Viroclinics Biosciences (Netherlands), Moderna, Inc. (USA), GlaxoSmithKline plc (UK), Sanofi (France), Novavax, Inc. (USA), Emergent BioSolutions Inc. (USA), Takeda Pharmaceutical Company Limited (Japan), and Other Active Players.
Q3: What are the segments of the Monkeypox Treatment Market?
A3: The Monkeypox Treatment Market is segmented into Treatment Type, Drug Class, Distribution Channel and region. By Treatment Type, the market is categorized into Antiviral Medications, Vaccines, Supportive Care. By Drug Class, the market is categorized into Antiviral Agents, Immune Modulators. By Distribution Channel, the market is categorized into Hospitals, Clinics, Retail Pharmacies, Online Pharmacies. By region, it is analyzed across North America (U.S., Canada, Mexico), Eastern Europe (Russia, Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe), Western Europe (Germany, UK, France, Netherlands, Italy, Spain, Rest of Western Europe), Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New Zealand, Rest of APAC), Middle East & Africa (Turkiye, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa), South America (Brazil, Argentina, Rest of SA).
Q4: What is the Monkeypox Treatment Market?
A4: Monkeypox Treatment Market centers on the pharmaceutical and medical industries in relation to the treatment of monkeypox, a viral disease resulting from the contact with the monkeypox virus, which is nearer to smallpox but not as malignant. The treatments involve controlling symptoms, avoiding the development of complications and slowing the transmission of the virus. Symptoms’ management interventions include antiviral drugs, vaccines, as well supportive care.
Q5: How big is the Monkeypox Treatment Market?
A5: Monkeypox Treatment Market Size Was Valued at USD 93.85 Million in 2023, and is Projected to Reach USD 226.05 Million by 2032, Growing at a CAGR of 10.26% From 2024-2032.
How to Buy a Report from eminsights.jp
On the product page, choose the license you want: Single-User License, Multi-User License or Enterprise License.
If you required report in your native language, then you can click on Translated Report button and fill out the form with report name and language you want, then our team will contact you as soon as possible.
Click the Buy Now button.
You will be redirected to the checkout page. Enter your company details and payment information.
Click Place Order to complete the purchase.
Confirmation: You’ll receive an order confirmation and our team will contact you shortly with your ordered report.
If you have any questions, fill out the contact form below or email us at bizdev@eminsights.net.
Thank you for choosing eminsights.jp!
